ScreenerHero

LNSRLENSAR, Inc.

NAS · US · Healthcare · Medical Devices · lensar.com
8.850USD+1.96%Mkt Cap: 106.64M $P/E: 43.40

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astig…

Industry Peers

Medical Devices
Screen all
ABT
Abbott Laboratories
$203.22BUSDP/E 37.8
SYK
Stryker Corporation
$125.74BUSDP/E 34.0
MDT
Medtronic plc
$118.91BUSDP/E 24.9
BSX
Boston Scientific Corporation
$71.03BUSDP/E 19.8
SHL
Siemens Healthineers AG
$48.43BUSDP/E 19.9
EW
Edwards Lifesciences Corporation
$52.11BUSDP/E 53.9
DXCM
DexCom, Inc.
$34.85BUSDP/E 36.5
GEHC
GE HealthCare Technologies Inc. Common Stock
$34.04BUSDP/E 17.2
PHIA
Koninklijke Philips N.V.
$25.08BUSDP/E 20.7
PHG
Koninklijke Philips N.V.
$26.90BUSDP/E 20.7
STE
STERIS plc
$23.19BUSDP/E 29.1
ZBH
Zimmer Biomet Holdings, Inc.
$19.26BUSDP/E 24.5
PEN
Penumbra, Inc.
$12.75BUSDP/E 79.7
SNN
Smith & Nephew plc
$12.40BUSDP/E 20.1
GMED
Globus Medical, Inc.
$11.29BUSDP/E 21.5
GKOS
Glaukos Corporation
$10.95BUSD
SN
Smith & Nephew plc
$9.84BUSDP/E 20.0
PODD
Insulet Corporation
$10.28BUSDP/E 27.5
BIO
Bio-Rad Laboratories, Inc.
$10.22BUSDP/E 46.5
DEMANT
Demant A/S
$8.82BUSDP/E 25.0
HeadlineSourceTime
Older
LENSAR (LNSR) Q2 2026 Earnings Call Transcript

ALLY system placements accelerate as recurring revenue hits 83% of total sales.

Motley Fool
LENSAR Inc (LNSR) (Q2 2026) Earnings Call Highlights: Record Revenue and Profitability Surge

LENSAR Inc (LNSR) posts 18% revenue growth and its strongest adjusted EBITDA to date, driven by a 20% jump in recurring revenue and expanding US market share.

GuruFocus.com
LENSAR Q2 Earnings Call Highlights

LENSAR (NASDAQ:LNSR) reported second-quarter 2026 revenue growth of 18% as the company continued to rebuild commercial momentum following the termination of its proposed merger with Alcon near the end of the first quarter. Chief Executive Officer Nick Curtis said the company returned to operating i

MarketBeat
LENSAR, Inc. Q2 2026 Earnings Call Summary

Moby summary of LENSAR, Inc.'s Q2 2026 earnings call

Moby
Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?
Zacks
How The LENSAR (LNSR) Story Is Shifting After The Failed Deal And New $10 Target
Simply Wall St.
Lensar (LNSR) Q1 2026 Earnings Transcript
Motley Fool
Lensar (LNSR) Q4 2025 Earnings Transcript
Motley Fool
LENSAR Q1 Earnings Call Highlights

LENSAR (NASDAQ:LNSR) executives told investors on Thursday that the company is moving past a “transaction-related holding pattern” after the termination of its planned merger, and is now refocusing on rebuilding commercial momentum around its ALLY femtosecond laser cataract platform. Management said

MarketBeat
How The Failed Alcon Deal Is Reframing The LENSAR (LNSR) Story And $10 Upside Potential

The updated analyst narrative around LENSAR now centers on a $10 price target that sits above a model fair value of $8.50 per share, giving you a clear reference point for how some on the Street are framing potential upside. Supporters connect this $10 mark to their view that ALLY System adoption can return to patterns seen before the Alcon deal was announced, while skeptics question whether that setup already bakes in optimistic execution. As you read on, you will see how both the bullish...

Simply Wall St.